Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Nvidia Corp (NVDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Nvidia Corp — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.81 (market cap $8.88B), while Nvidia Corp trades at $217.47 (market cap $5.34T). The key difference: Nvidia Corp is far larger — about 601.4× Kymera Therapeutics Inc. Common Stock's market cap, and Nvidia Corp pays a 0.45% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Nvidia Corp for 116 Days on average.
| KYMR | NVDA | |
|---|---|---|
Market Cap | $8.88B | $5.34T |
Volume | 1,028,790 | 117,762,243 |
Sector | Health | Technology |
52-Week High | $127.31 | $239.27 |
52-Week Low | $55.80 | $165.17 |
Typical Hold Time | 0 Days | 116 Days |
Enterprise Value | $8.27B | $5.32T |
Dividend Yield | — | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
NVIDIA (NVDA) trades at $228.52, up 0.97% with strong fundamental performance including 63.66% net income margin and 117.21% ROE. The stock shows bullish technical signals with recent earnings beats and analyst consensus price target of $339.17 representing 48% upside potential. Revenue growth accelerated to $130.5B in 2025 with projected $303B for 2026.
NVIDIA maintains dominant AI market position with robust financials, though elevated valuations (P/E 27.98, P/S 17.82) and competition pose risks. Strong institutional support (75.95% buy ratings) and cash flow growth support long-term outlook, but investors should monitor execution against high expectations and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →
